Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Ireland
  4. Irish Stock Exchange
  5. Elan Corporation Ltd
  6. News
  7. Summary
    DRX   IE0003072950

ELAN CORPORATION LTD

(DRX)
SummaryChartsNewsCompany 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Ex-SAC manager Martoma fails to end part of insider case

12/17/2013 | 08:14pm EDT
Mathew Martoma leaves Manhattan Federal Court after facing charges on an insider trading scheme in New York

NEW YORK (Reuters) - A federal judge on Tuesday rejected former SAC Capital Advisors LP portfolio manager Mathew Martoma's request to dismiss some insider trading charges because they were based on transactions not covered under U.S. securities laws.

U.S. District Judge Paul Gardephe in Manhattan said Martoma's alleged trades in American depository receipts of Irish drugmaker Elan Corp (>> Elan Corporation, plc) qualified as domestic transactions covered by U.S. securities laws.

As a result, the judge rejected Martoma's request to dismiss one of two securities fraud charges, as well as related allegations in a conspiracy count. The defendant has pleaded not guilty to the three counts, and faces a January 6 trial.

Martoma's lawyer Richard Strassberg, a partner at Goodwin Procter, declined to comment.

SAC, the Stamford, Connecticut-based hedge fund run by billionaire Steven A. Cohen, pleaded guilty on November 8 to fraud and agreed to pay $1.8 billion, including prior regulatory settlements, to end a federal insider trading probe. Cohen has not been charged with a crime.

Prosecutors accused Martoma of helping SAC affiliate CR Intrinsic Investors avoid $276 million of losses in 2008 by recommending that it sell shares of Elan and Wyeth, based on a doctor's tips about poor trial results for a diabetes drug. Wyeth is now owned by Pfizer Inc (>> Pfizer Inc.).

Martoma argued that a key U.S. insider trading law, Section 10(b) of the Securities Exchange Act of 1934, did not cover the Elan trades because a 2010 U.S. Supreme Court decision limited the reach of that law to domestic transactions.

The 2nd U.S. Circuit Court of Appeals, which hears appeals from Manhattan, in August extended that decision, Morrison v. National Australia Bank Ltd, in finding that U.S. criminal securities fraud laws don't extend outside the country.

But Gardephe said the Elan ADRs were listed and traded on the New York Stock Exchange, "an official American securities exchange," and that Martoma cited no case to show that Section 10(b) should not apply.

The judge also rejected Martoma's argument that because Elan's ADRs were mere "receipts," the trades qualified as foreign because "liability was incurred and title passed" when Elan deposited the associated shares with the Bank of Ireland.

"Defendant's arguments are not persuasive," Gardephe said. "Here, it is undisputed that the Elan ADRs at issue were traded on the NYSE, which means that the formation of contracts for those trades, the passing of title to those securities, and the incurring of liability on the part of sellers and purchasers of those ADRs occurred in the United States."

U.S. prosecutors have charged eight SAC employees with insider trading. Six have pleaded guilty, while Martoma and portfolio manager Michael Steinberg pleaded not guilty. Jurors began deliberating in Steinberg's trial on Tuesday.

The case is U.S. v. Martoma, U.S. District Court, Southern District of New York, No. 12-cr-00973.

(Reporting by Jonathan Stempel; Editing by Alden Bentley, Andrew Hay and Vicki Allen)

By Jonathan Stempel

Stocks treated in this article : Pfizer Inc., Elan Corporation, plc

ę Reuters 2013
Stocks mentioned in the article
ChangeLast1st jan.
BANK OF IRELAND GROUP PLC -2.19% 4.86 Real-time Quote.50.58%
ELAN CORPORATION LTD -0.39% 12.71 End-of-day quote.0.00%
NATIONAL AUSTRALIA BANK LIMITED -1.97% 27.34 End-of-day quote.20.97%
All news about ELAN CORPORATION LTD
2014With eye on tax rates, Horizon Pharma buys Ireland's Vidara
RE
2013Ex-SAC manager Martoma fails to end part of insider case
RE
2013ELAN CORPORATION, PLC : Perrigo Company and Elan Corporation Plc Receive Irish H..
PU
2013Ex-SAC trader points to Cohen testimony in insider trading case
RE
2013ELAN CORPORATION, PLC : Elan Announces Shareholder Approval of its Acquisition b..
BU
2013Elan wins shareholder approval to complete Perrigo sale
RE
2013The prosecutors with SAC Capital in their crosshairs
RE
2013ELAN CORPORATION, PLC : Elan Reports Third Quarter 2013 Financial Results
BU
2013EXCLUSIVE - TPG-BACKED APTALIS PHARM : sources
RE
2013ELAN CORPORATION, PLC : Elan Announces Webcast of Third Quarter 2013 Financial R..
BU
More news
Analyst Recommendations on ELAN CORPORATION LTD
More recommendations
Chart ELAN CORPORATION LTD
Duration : Period :
Elan Corporation Ltd Technical Analysis Chart | DRX | IE0003072950 | MarketScreener
Sector and Competitors
1st jan.Capi. (M$)
ELAN CORPORATION LTD0.00%0
MODERNA, INC.311.65%173 588
LONZA GROUP AG32.35%60 074
IQVIA HOLDINGS INC.43.07%49 116
CELLTRION, INC.-23.26%31 904
SEAGEN INC.-10.81%28 420